ZA200905467B - Method for activation of helper T cell and composition for use in the method - Google Patents
Method for activation of helper T cell and composition for use in the methodInfo
- Publication number
- ZA200905467B ZA200905467B ZA200905467A ZA200905467A ZA200905467B ZA 200905467 B ZA200905467 B ZA 200905467B ZA 200905467 A ZA200905467 A ZA 200905467A ZA 200905467 A ZA200905467 A ZA 200905467A ZA 200905467 B ZA200905467 B ZA 200905467B
- Authority
- ZA
- South Africa
- Prior art keywords
- helper
- activation
- cell
- composition
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 210000002443 helper t lymphocyte Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007047317 | 2007-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200905467B true ZA200905467B (en) | 2010-05-26 |
Family
ID=39721287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200905467A ZA200905467B (en) | 2007-02-27 | 2009-08-05 | Method for activation of helper T cell and composition for use in the method |
Country Status (26)
Country | Link |
---|---|
US (2) | US10139395B2 (fr) |
EP (1) | EP2119778B1 (fr) |
JP (2) | JP5225262B2 (fr) |
KR (1) | KR101598228B1 (fr) |
CN (6) | CN104774910B (fr) |
AU (1) | AU2008220031B2 (fr) |
BR (1) | BRPI0808084A2 (fr) |
CA (1) | CA2677075C (fr) |
CY (1) | CY1117150T1 (fr) |
DK (1) | DK2119778T3 (fr) |
ES (1) | ES2559062T3 (fr) |
HK (1) | HK1138321A1 (fr) |
HR (1) | HRP20160020T1 (fr) |
HU (1) | HUE027472T2 (fr) |
IL (1) | IL200161A (fr) |
MX (2) | MX2009009168A (fr) |
MY (2) | MY164867A (fr) |
NZ (3) | NZ599161A (fr) |
PL (1) | PL2119778T3 (fr) |
PT (1) | PT2119778E (fr) |
RU (2) | RU2680539C2 (fr) |
SG (1) | SG177998A1 (fr) |
SI (1) | SI2119778T1 (fr) |
UA (1) | UA101608C2 (fr) |
WO (1) | WO2008105462A1 (fr) |
ZA (1) | ZA200905467B (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101213015B1 (ko) | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
EP3117836A1 (fr) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Peptides wt-1 immunogènes et leurs utilisations |
CN104774910B (zh) | 2007-02-27 | 2018-04-10 | 株式会社癌免疫研究所 | 活化辅助t细胞的方法以及用于该方法的组合物 |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
CA2783550A1 (fr) * | 2009-12-08 | 2011-06-16 | Wilson Wolf Manufacturing Corporation | Procedes ameliores de culture cellulaire pour therapie cellulaire adoptive |
US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
ES2849187T3 (es) | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
JP6122779B2 (ja) * | 2011-09-14 | 2017-04-26 | 株式会社癌免疫研究所 | 抗wt1抗体の測定方法 |
CN104136609B (zh) * | 2011-12-14 | 2016-12-07 | 国立大学法人高知大学 | 辅助性t细胞诱导多肽的修饰 |
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
EP2896693A4 (fr) | 2012-09-12 | 2016-10-12 | Int Inst Cancer Immunology Inc | Gènes de récepteur de lymphocyte t auxiliaire spécifique d'un antigène |
JP6530192B2 (ja) | 2012-12-17 | 2019-06-12 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CN116789792A (zh) | 2013-01-15 | 2023-09-22 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
EP3112378B1 (fr) * | 2014-02-26 | 2020-06-24 | Tella, Inc. | Polypeptide antigénique wt1, et agent antitumoral contenant ledit polypeptide |
CN108350411B (zh) | 2015-06-25 | 2021-06-22 | 白川利朗 | 口服肿瘤疫苗 |
JP6810877B2 (ja) | 2016-12-26 | 2021-01-13 | 国立大学法人神戸大学 | 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療 |
KR20220129567A (ko) | 2019-12-31 | 2022-09-23 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
KR102647825B1 (ko) * | 2021-07-22 | 2024-03-14 | 서울대학교산학협력단 | 항-hla-dp 단클론 항체 및 이의 용도 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
CN1560078B (zh) | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
CA2349442C (fr) | 1998-09-30 | 2012-12-04 | Corixa Corporation | Compositions et methodes relatives a une immunotherapie specifique du wt1 |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
CA2401070A1 (fr) | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions et methodes destinees au diagnostic et a la therapie du mesotheliome malin |
CA2440303C (fr) | 2001-03-22 | 2013-03-19 | Haruo Sugiyama | Peptide modifie wt1 |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
WO2003002142A1 (fr) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Vaccin anticarcinogene contenant un antigene tumoral base sur un produit de gene wt1 suppresseur de tumeur et des liposomes cationiques |
US7553494B2 (en) * | 2001-08-24 | 2009-06-30 | Corixa Corporation | WT1 fusion proteins |
US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的t細胞の誘導方法 |
ATE466084T1 (de) | 2002-06-12 | 2010-05-15 | Int Inst Cancer Immunology Inc | Hla-a24-restringiertes krebsantigenpeptid |
ES2538486T3 (es) | 2002-09-12 | 2015-06-22 | International Institute Of Cancer Immunology, Inc. | Preparación de péptidos antigénicos contra el cáncer |
ATE442378T1 (de) | 2002-09-20 | 2009-09-15 | Int Inst Cancer Immunology Inc | Substituierte wt1-peptide |
US20060217297A1 (en) | 2003-01-15 | 2006-09-28 | Haruo Sugiyama | Dimerized peptide |
ES2478446T3 (es) | 2003-06-27 | 2014-07-22 | International Institute Of Cancer Immunology, Inc. | Método de selección de pacientes candidatos para la vacuna contra WT1 |
KR101213015B1 (ko) * | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Wt1 로부터 유도된 hla-dr 결합성 항원 펩티드 |
US7488718B2 (en) * | 2003-12-01 | 2009-02-10 | Sloan Kettering Institue For Cancer Research | Synthetic HLA binding peptide analogues and uses thereof |
SI1731605T1 (sl) * | 2004-03-31 | 2010-07-30 | Internat Inst Of Cancer Immunolog Inc | Peptidi antigena karcinoma izvedeni iz WT1 |
JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Hlaクラスii拘束性wt1抗原ペプチド |
AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
CN101336249A (zh) | 2005-11-30 | 2008-12-31 | 株式会社癌免疫研究所 | 新型肽化合物 |
PL1988163T3 (pl) | 2006-02-22 | 2012-11-30 | Int Inst Cancer Immunology Inc | Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna |
EP3117836A1 (fr) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Peptides wt-1 immunogènes et leurs utilisations |
CA2886619A1 (fr) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Peptide wt1 a restriction hla-a<sp>*</sp>1101 et composition pharmaceutique le contenant |
CN104774910B (zh) | 2007-02-27 | 2018-04-10 | 株式会社癌免疫研究所 | 活化辅助t细胞的方法以及用于该方法的组合物 |
EP3173480A3 (fr) | 2007-03-05 | 2017-08-16 | International Institute of Cancer Immunology, Inc. | Gène du récepteur des lymphocytes t spécifiques de l'antigène du cancer, peptide codé par le gène et utilisation de ceux-ci |
AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
ES2849187T3 (es) | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
JP6530192B2 (ja) | 2012-12-17 | 2019-06-12 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
-
2008
- 2008-02-27 CN CN201510102294.3A patent/CN104774910B/zh active Active
- 2008-02-27 US US12/449,765 patent/US10139395B2/en active Active
- 2008-02-27 MX MX2009009168A patent/MX2009009168A/es active IP Right Grant
- 2008-02-27 MX MX2014002596A patent/MX352947B/es unknown
- 2008-02-27 EP EP08712039.0A patent/EP2119778B1/fr active Active
- 2008-02-27 CN CN201310009518.7A patent/CN103088103B/zh active Active
- 2008-02-27 PT PT87120390T patent/PT2119778E/pt unknown
- 2008-02-27 AU AU2008220031A patent/AU2008220031B2/en active Active
- 2008-02-27 SG SG2012004180A patent/SG177998A1/en unknown
- 2008-02-27 RU RU2014104572A patent/RU2680539C2/ru active
- 2008-02-27 CN CN201310058504.4A patent/CN103149366B/zh active Active
- 2008-02-27 DK DK08712039.0T patent/DK2119778T3/en active
- 2008-02-27 WO PCT/JP2008/053417 patent/WO2008105462A1/fr active Application Filing
- 2008-02-27 CA CA2677075A patent/CA2677075C/fr active Active
- 2008-02-27 KR KR1020097017594A patent/KR101598228B1/ko active IP Right Grant
- 2008-02-27 BR BRPI0808084-4A patent/BRPI0808084A2/pt not_active Application Discontinuation
- 2008-02-27 JP JP2009501276A patent/JP5225262B2/ja active Active
- 2008-02-27 CN CN201310009095.9A patent/CN103103246B/zh active Active
- 2008-02-27 MY MYPI2013001057A patent/MY164867A/en unknown
- 2008-02-27 NZ NZ599161A patent/NZ599161A/xx unknown
- 2008-02-27 NZ NZ578721A patent/NZ578721A/en unknown
- 2008-02-27 HU HUE08712039A patent/HUE027472T2/en unknown
- 2008-02-27 CN CN201410573477.9A patent/CN104312974B/zh active Active
- 2008-02-27 CN CN200880006096A patent/CN101622344A/zh active Pending
- 2008-02-27 ES ES08712039.0T patent/ES2559062T3/es active Active
- 2008-02-27 MY MYPI20093253A patent/MY158219A/en unknown
- 2008-02-27 NZ NZ599160A patent/NZ599160A/en unknown
- 2008-02-27 RU RU2009135802/10A patent/RU2009135802A/ru unknown
- 2008-02-27 SI SI200831564T patent/SI2119778T1/sl unknown
- 2008-02-27 UA UAA200909812A patent/UA101608C2/uk unknown
- 2008-02-27 PL PL08712039T patent/PL2119778T3/pl unknown
-
2009
- 2009-07-30 IL IL200161A patent/IL200161A/en active IP Right Grant
- 2009-08-05 ZA ZA200905467A patent/ZA200905467B/xx unknown
-
2010
- 2010-05-04 HK HK10104389.9A patent/HK1138321A1/xx unknown
-
2013
- 2013-01-31 JP JP2013017370A patent/JP5714619B2/ja active Active
-
2016
- 2016-01-11 HR HRP20160020TT patent/HRP20160020T1/hr unknown
- 2016-01-20 CY CY20161100054T patent/CY1117150T1/el unknown
-
2018
- 2018-10-18 US US16/163,682 patent/US11555814B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL200161A0 (en) | Method for activation of helper t cell and composition for use in the method | |
IL267138A (en) | Improved composition of cells and methods for its preparation | |
GB2443823B (en) | Devices and methods for use in construction | |
SG10201605686XA (en) | Polishing Composition And Polishing Method Using The Same | |
IL202329A0 (en) | Methods and compositions for stimulating cells | |
EP2180933A4 (fr) | Corps poreux et procédés | |
ZA200905886B (en) | Methods and kits for administering probiotics | |
EP2189519A4 (fr) | Instrument de culture cellulaire et procédé de culture cellulaire l'utilisant | |
HK1147254A1 (en) | 5-anilinoimidazopyridines and methods of use 5- | |
EP2129429A4 (fr) | Appareil d'ancrage et procédés d'utilisation | |
EP2308884A4 (fr) | Procédé de production d'un alkylhalogénohydrosilane substitué par un groupement hétéro en et son utilisation | |
GB0605702D0 (en) | Materials and methods for immune cell stimulation | |
EP2324956A4 (fr) | Composition de polissage et procédé de polissage l'utilisant | |
GB0709781D0 (en) | Composition and method | |
IL206125A0 (en) | Azaindolizines and methods of use | |
GB0724967D0 (en) | Composition and method | |
GB0620930D0 (en) | Composition and method for use thereof | |
ZA201004894B (en) | Nuctraceutical composition and methods of use | |
EP2115127A4 (fr) | Procédés et compositions pour améliorer la santé de cellules en culture | |
ZA201004893B (en) | Nuctraceutical composition and methods of use | |
ZA201008261B (en) | Non-hydrating plaster composition and method | |
MY152929A (en) | Polishing composition and polishing method | |
EP2348865A4 (fr) | Bêta-hydroxy-gamma-aminophosphonates, leurs méthodes de préparation et leur utilisation | |
EP2185685A4 (fr) | Nouveaux procédés et nouvelles lignées cellulaires | |
TWI365216B (en) | Polishing composition for polishing lithium aluminate and method of using the same |